Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

2.9K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
2.9K
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

2.9K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.9K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

381
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
381
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

241
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
241
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

373
The pathophysiology of pneumonia involves the following steps:
373
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

878
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
878

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute exacerbation in fibrotic interstitial lung disease: An International Working Group Report.

American journal of respiratory and critical care medicine·2026
Same author

Type I interferon pathway activation in connective tissue disease associated interstitial lung disease.

Frontiers in immunology·2026
Same author

Design of a randomized controlled trial comparing hybrid care with standard care for people with pulmonary fibrosis.

Respiratory research·2026
Same author

Sotatercept in TBX4 Associated Heritable Pulmonary Arterial Hypertension: A Case Report of a Super Responder.

Pulmonary circulation·2026
Same author

Efficacy and safety of nerandomilast in patients with autoimmune disease-related progressive pulmonary fibrosis in the FIBRONEER-ILD trial.

Annals of the rheumatic diseases·2026
Same author

[Diagnosis and management of pulmonary sarcoidosis].

Nederlands tijdschrift voor geneeskunde·2026

Related Experiment Video

Updated: Jul 31, 2025

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

172

Idiopathic pulmonary fibrosis.

Thomas Koudstaal1, Marlies S Wijsenbeek1

  • 1Center for Interstitial Lung Diseases and Sarcoidosis, Department of Pulmonary Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands.

Presse Medicale (Paris, France : 1983)
|May 8, 2023
PubMed
Summary

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease affecting millions globally. Current treatments slow decline, but new therapies are under investigation to improve outcomes for this devastating condition.

Keywords:
GeneticsIdiopathic pulmonary fibrosisInflammation and immunityTherapeutic management

More Related Videos

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

653
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.0K

Related Experiment Videos

Last Updated: Jul 31, 2025

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

172
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

653
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.0K

Area of Science:

  • Pulmonology
  • Pathophysiology
  • Medical Research

Background:

  • Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease impacting millions worldwide.
  • IPF significantly reduces quality of life and has a median survival of only 3 years without treatment.
  • The disease involves repetitive lung injury, inflammation, and aberrant tissue remodeling leading to fibrosis.

Purpose of the Study:

  • To provide a comprehensive overview of IPF epidemiology and pathophysiology.
  • To detail current diagnostic and therapeutic strategies for IPF.
  • To review emerging therapies and ongoing clinical trials for IPF.

Main Methods:

  • Literature review of epidemiological data on IPF.
  • Analysis of current understanding of IPF pathogenesis.
  • Synthesis of information on diagnostic criteria and management guidelines for IPF.
  • Review of approved therapies (pirfenidone, nintedanib) and investigational treatments.

Main Results:

  • IPF affects approximately 3 million people globally, with increasing incidence in older populations.
  • Current therapies like pirfenidone and nintedanib slow lung function decline but do not cure IPF.
  • Multiple new therapeutic approaches targeting diverse pathways are in clinical trials.

Conclusions:

  • IPF remains a devastating disease with poor prognosis despite available treatments.
  • Accurate diagnosis relies on multidisciplinary assessment, excluding other conditions.
  • Ongoing research offers hope for more effective IPF therapies in the future.